source
- Cell and gene therapy funding climbs to $2.2 billion in Q3 despite safety setbacks in CAR-T trialsSail Biomedicine’s $925 million agreement with Johnson & Johnson helped lift venture capital money into the cell and gene therapy (CGT) space during the third quarter. CGT attracted $2.2 billion a…
- FDA policy allowing compounding of unapproved peptides raises safety and development concernsThe Department of Health and Human Services recently approved the compounding of six peptide products that have not received FDA approval. This move expands the list of bulk substances that traditi…